You are here: Industry Insights > Monsanto

News List

California Couple Awarded $2 Billion in Roundup Lawsuit drugs
May 15, 2019
An elderly California couple who said their cancer was caused by Monsanto's weed killer Roundup was awarded just over $2 billion by a jury in Oakland on Monday.
Monsanto liable for French farmer’s ill health bbc
April 16, 2019
US biotech giant Monsanto is legally responsible for the ill health of a farmer who ingested its weedkiller product, a French court has ruled.
Post-Monsanto Era of Bayer Group: To Lay off 10,000+ Employees, Scale Back Business, and Develop Life Science PharmaSources/Youyi
January 08, 2019
Bayer formally acquired the U.S. agricultural company: Monsanto for a price of USD63 billion on June 7, 2018 upon approval of the relevant U.S. and European regulators.
Bayer says Monsanto India integration to complete in one year expressbpd
September 25, 2018
Bayer completed the deal to acquire US-based Monsanto recently and the acquisition of Monsanto has been completed globally but it is still in process in India
Roundup cancer verdict sends Bayer shares sliding Reuters
August 16, 2018
Bayer's newly acquired Monsanto was ordered to pay $289 million in damages in the first of possibly thousands of U.S. lawsuits over alleged links between a weedkiller and cancer.
Bayer HealthCare's faltering even before Monsanto enters the fold fiercepharma
March 01, 2018
Industry watchers were worried about Bayer neglecting its healthcare division after the company chased down a megamerger with agrochemical giant Monsanto. But that deal hasn’t even closed yet, and healthcare sales are already showing cause for concern.
Another record year for Bayer - good progress with the acquisition of Monsanto worldpharmanews
February 24, 2017
Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent) to EUR 46,769 million (2015: EUR 46,085 million).
Flashback 2016! biospectrumasia
January 16, 2017
Year 2016 was a mixed year for the pharma industry with increasing number of acquisitions and mergers, foreign investments, layoffs, regulatory hurdles and new challenges. Biospectrum takes a look at the top Mergers and Acquisitions in 2016